Searched for
GLENN SALDANHA
Indian pharma may take AI pill to cut time and costs in drug R&DIndian pharmaceutical giants Sun Pharma and Glenmark are embracing Artificial Intelligence to speed up new drug creation. This technology p...- Indian Pharmaceutical Alliance appoints Zydus Lifesciences MD Sharvil Patel as new presidentThe Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Gle...
- Glenmark Q1 Results: Profit declines 31% to Rs 211 crore"We delivered a strong double digit growth in our base business during the quarter excluding the impact of COVID-related products," Glenmar...
- Glenmark looks to file up to 25 product applications annuallyWe expect to file 20-25 abbreviated new drug applications each year over the next 5 years and launch 10-20 products annually," Glenmark MD ...
- Expect to reduce net debt by about Rs 300 crore: Glenn Saldanha, Glenmark PharmaceuticalsThere is a bunch of products approvals coming through for most of the Indian companies that do not have any outstanding compliance issues.
- For Glenn Saldanha, innovation is the new Vitamin for Glenmark's successInvestors complained, competitors were mystified and Saldanha's father was skeptical. Nevertheless, Saldanha pressed ahead in the painstaki...
- Launch of gZetia positively impacted US business: Glenn Saldanha, GlenmarkIn an exclusive interview to ET Now, Glenn Saldanha, CMD, Glenmark, said next few quarters will be strong due to gZetia.
- Glenmark Pharma draws up capex of USD 300 mn over next 3 yearsGlenmark along with its subsidiaries operate 17 manufacturing facilities across four countries and has five research and development center...
- Pricing pressure within channels leading to some erosion in base business: Glenn Saldanha, Glenmark"We have taken significant knocks on currency in most parts of the world, particularly in the emerging markets."
- US will be a strong driver for the company in the next few years: Glenn Saldanha, Glenmark Pharmaceuticals Ltd"We ended up launching, getting six or seven approvals over the last three or four months, and most of them were launched in the quarter."
- Expect 12-15% growth from US market in FY15: Glenn SaldanhaWe did not get any new approval in Q1 and last year also we struggled a little bit in terms of getting product approvals, says Glenn Saldan...
- Will be able to sustain margins as topline is expected to grow: Glenmark Pharma"On the R&D side, we continue to have a robust pipeline of products. We have two monoclonal antibodies ready to enter the clinics between t...
- Don’t see 30% growth being sustainable going forward: Glenn Saldanha, Glenmark Pharma"With slowdown in India, we are not sure how things will pan out going forward, but the 30% growth is not sustainable going forward," says ...
- Crofelemer approval a big positive for company: Glenn Saldanha, Glenmark Pharma"There is another $6 million that Salix is likely to pay us for the facility that we are working on for the supplies of Crofelemer."
- Glenmark Pharma aims at Rs 5,000 crore revenue during FY13, focus on USGlenmark Pharmaceuticals today said it is aiming for up to 30 per cent growth in revenues this fiscal to touch Rs 5,000 crore.
- Glenmark Pharmaceuticals to initiate filing for Crofelemer as Salix submits NDAGlenmark is going full steam ahead with the launch of Crofelemer post the issue of Napo Pharma's claim of termination of the deal.
- Napo termination will not impact company: GlenmarkIn an interview with ET Now, Glenn Saldanha, Chairman and Managing Director, Glenmark, gives his views on the company's strategies. Excerpt...
- We anticipate margins between 22% to 23% for the full year: Glenn Saldanha, Glenmark Ltd.Glenn Saldanha, Chairman and Managing Director, Glenmark Ltd., in an interview with ET Now, speaks about the company’s performance in the q...
- Glenmark Pharma raises Rs 413 crore through QIPGlenmark Pharmaceuticals has raised Rs 413 crore through its recently concluded Qualified Institutional Placement, which will be used towar...
- Drug research was way forward: GlenmarkAfter much analysis, consultants advised Glenmark Pharmaceuticals to stay away from research as it lacked the resources needed for innovati...
Load More
